Group 1 - The core viewpoint of the news is the strategic collaboration between Huajian Medical and Renhe Pharmaceutical to establish the world's first OTC-focused Real World Asset (RWA) exchange in the United States, highlighting the growing interest and cautious optimism in the RWA sector [1][6][9] - The RWA market is gaining traction, with a projected market size of $16 trillion by 2030, prompting numerous companies in both A-shares and Hong Kong stocks to enter the space [2][5] - Huajian Medical's "ETHK global RWA exchange" aims to create a comprehensive ecosystem for asset tokenization, connecting various industries with financial institutions [5][6][9] Group 2 - The RWA sector is characterized by a disparity in development between the U.S. and China, with the U.S. having a more established infrastructure for asset tokenization [5] - Companies like Langxin Group and GCL-Poly Energy have taken the lead in RWA practices in China, successfully completing projects that tokenize renewable energy assets [2] - The collaboration between Huajian Medical and Renhe Pharmaceutical is seen as a significant step for Chinese listed companies to explore the RWA market, especially with the evolving global regulatory framework [9] Group 3 - Successful RWA initiatives require high-quality, liquid assets, with Renhe Pharmaceutical's strong brand portfolio providing significant tokenization potential [8] - The RWA industry involves various services such as asset verification, compliance auditing, and liquidity provision, benefiting related financial service providers [8] - Huajian Medical's strategic acquisitions and compliance capabilities position it well to facilitate the tokenization and cross-border trading of real-world assets [8][9]